Global Premature Ejaculation Treatment Market 2017-2021
About Premature Ejaculation Treatment
Premature ejaculation is one of the most common sexual dysfunctions occurring in men. Ejaculation happens sooner than desired, either shortly or before penetration, resulting in distress to either one or both partners involved in sexual intercourse. There is no exact cause that can be associated with the condition though mostly, premature ejaculation can be attributed to personal distress and anxiety. It can affect an individual's relationship with his partner. Premature ejaculation is the most common sexual disorder found in men aged between 18 to 59. Some of the effective treatment options available include psychological counseling, medications, sexual techniques that delay ejaculation, or a combination of these treatments.
Technavio’s analysts forecast the global premature ejaculation treatment market to grow at a CAGR of 8.71% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global premature ejaculation treatment market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Premature Ejaculation Treatment Market 2017-2021
Technavio recognizes the following companies as the key players in the global premature ejaculation treatment market: Absorption Pharmaceuticals, Bayer, Eli Lilly, and Regent Pacific Group
Other Prominent Vendors in the market are: Dong-A Pharmaceutical, Emcure, Futura Medical, GlaxoSmithKline, NeuroHealing Pharmaceuticals, and Pfizer
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is Growing online retail sales of drugs. The advent of the internet has reduced the time involved in the physical buying and selling of products and services for buyers and sellers. In terms of growth of different retail channels through which sexual disorder-related drugs are offered, online retailing will be the fastest channel of distribution during the forecast period. The success of online retailing can be attributed to factors such as the availability of a broad range of products, quick delivery services, and highly competitive prices.”
According to the report, one of the major drivers for this market is High use of off-label drugs. The global premature ejaculation treatment market has witnessed the increased use of off-label drugs belonging to different drug classes such as SSRIs (fluvoxamine, paroxetine, sertraline, and fluoxetine) and PDE5 inhibitors (Cialis, VIAGRA, and Levitra). Pharmacological modification of the ejaculatory response in patients with the condition represents a novel approach for the treatment of premature ejaculation and will lead to the gradual replacement of psychosexual counseling, which was previously regarded as the cornerstone of premature ejaculation treatment.
Further, the report states that one of the major factors hindering the growth of this market is Alternative treatments. While the market has several drugs in the pipeline, the growing number of premature ejaculation cases globally has led to an increase in the number of alternative treatment methods for the disease. Some of the alternate treatment methods include counseling, homeopathy, psychotherapy, yoga, and herbal therapy. There are also other natural treatment options for premature ejaculation such as ginseng tea or supplement, raw almond milk, and Ayurvedic dietary changes that can help in delaying ejaculation.
Absorption Pharmaceuticals, Bayer, Eli Lilly, Regent Pacific Group, Dong-A Pharmaceutical, Emcure, Futura Medical, GlaxoSmithKline, NeuroHealing Pharmaceuticals, and Pfizer